Utilizing DTC sample collection with a surrogate virus neutralization test (sVNT) to identify neutralizing antibodies against COVID-19 variants of concern

Thursday, July 28
12:30 – 12:50 p.m.
Exhibit Hall Theater 1
Presentation by GenScripts


SARS-CoV-2 vaccine efficacy testing faces challenges as new variants rise and vaccine immunity wanes. Evidence supports the correlation between neutralizing antibody titers and protection from this dangerous virus. Recent studies show only 40% of fully vaccinated elderly (over 80 years of age) and immunocompromised people have these protective antibodies. Furthermore, Israel’s early vaccination program exclusively using the Pfizer vaccine has shown waning population immunity after about six months post-vaccination. This led to an uptick in infections particularly from the Omicron and Delta variants. Additionally, breakthrough infections are happening globally due to rapid spread of Omicron VOC. This talk explores the key questions associated with the healthcare implications of SARS-CoV-2 and how neutralizing antibody testing using a direct-to-consumer SVNT may help in determining individual need for booster and protection against COVID-19 VOCs.


After attending this session, participants will be able to:

  • Understand how neutralizing antibodies are a determining factor for vaccine booster
  • Understand use of a sVNT to determine neutralizing activity against VOCs
  • Know more about direct-to-consumer (DTC) sample collection with a sVNT



Michael Lau, PhD
Senior Director of Corporate Strategy
GenScripts USA Inc

Pankaj Singhal, PhD
President & CEO
GattaCo Inc

Anders H. Berg, MD, PhD
Vice Chair, CLIA and Laboratory Operations
Cedars Sinai Medical Center